|
Sign In to gain access to subscriptions and/or personal tools.
|
Comparison of high- versus low-tissue affinity ACE-inhibitor treatment on circulating aldosterone levels in patients with chronic heart failure
Timothy J Vittorio
Albert Einstein College of Medicine, Division of Cardiology, Bronx, New York, NY, USA, t_vittorio{at}hotmail.com
Kartikya Ahuja
Albert Einstein College of Medicine, Division of Cardiology, Bronx, New York, NY, USA
Michael Kasper
New York University School of Medicine, Department of Medicine, New York, NY, USA
Haris Turalic
New York University School of Medicine, Department of Medicine, New York, NY, USA
Chi-Hong Tseng
New York University School of Medicine, Department of Medicine, New York, NY, USA
Ulrich P Jorde
Columbia University College of Physicians and Surgeons, Division of Cardiology, New Youk, NY, USA
Chirayu Gor
New York University School of Medicine, Department of Medicine, New York, NY, USA
Introduction. Previous animal studies of chronic heart failure (CHF) suggest that angiotensin-converting enzyme (ACE) inhibitors of differing tissue avidity provide varying levels of renin-angiotensin system (RAS) suppression. Human studies have not consistently confirmed these animal findings. We hypothesised that production of circulating aldosterone (ALDO) would be suppressed to a greater extent in subjects treated with an ACE-inhibitor of higher tissue avidity. We randomised subjects with stable CHF to receive the low-tissue affinity ACE-inhibitor enalapril (ENAL) or the high-tissue affinity ACE-inhibitor trandolapril (TRAN), and assessed circulating ALDO levels at baseline and after eight weeks of treatment.
Methods. Thirty clinically stable subjects with CHF and left ventricular ejection fraction (LVEF ) < 40% who were in a steady-state fluid balance were enrolled into a prospective, randomised double-blind trial. After a one month run-in period for standardisation to initial ACE-inhibition with ENAL, baseline circulating ALDO levels were measured and patients were randomised to receive ENAL 40 mg versus O TRAN 4 mg (or the maximally tolerated doses) for eight weeks. Final determination of ALDO levels were made at the end of the 8-week study period.
Results. Baseline clinical characteristics including age, diabetes, LVEF, serum sodium, potassium and creatinine concentrations, and background medications were similar in both groups. We found no statistically significant difference in circulating ALDO levels between the ENAL and TRAN groups at the end of the 8-week study period. [ENAL (12.6 vs. 13.3 ng/dL);TRAN (12.5 vs. 14.5 ng/dL);p=NS].
Conclusion. We found no statistically significant difference in circulating ALDO levels between high- and low-tissue affinity ACE-inhibitor therapy. Further studies assessing ALDO production at the tissue level is warranted.
Key Words: renin-angiotensin system • aldosterone • high affinity • low affinity • ACE-inhibitor
References
- Weber KT Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.[Free Full Text]
- Pitt B., Zannad F., Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.[Abstract/Free Full Text]
- Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.[Abstract/Free Full Text]
- Jorde UP, Vittorio TJ, Dimayuga CA et al. Comparison of< suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure. Am J Cardiol 2004;94:1501-05.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hornig B., Arakawa N., Haussmann D. et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart A failure. Circulation 1998;98:2842-8.[Abstract/Free Full Text]
- Ruzicka M., Skarda V., Leenen FH Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation 1995;92:3568-73.[Abstract/Free Full Text]
- Mori T., Nishimura H., Okabe M. et al. Cardioprotective effects of quinapril after myocardial infarction in hypertensive rats. Eur J Pharmacol 1998;348:229-34.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Fornes P., Richer C., Pussard E. et al. Beneficial effects of trandolapril on experimentally induced congestive heart failure in rats. Am J Cardiol 1992;70:43D-51D.[CrossRef][Medline]
[Order article via Infotrieve]
- Richer C., Mulder P., Fornes P. et al. Long-term treatment with trandolapril opposes cardiac remodeling and prolongs survival after myocardial infarction in rats. J Cardiovasc Pharmacol 1992;20:147-56.[Web of Science][Medline]
[Order article via Infotrieve]
- Okumura Y., Nasa Y., Sanbe A. et al. Effects of long-term treatment with trandolapril on augmented vasoconstriction in rats with chronic heart failure. J Card Fail 1996;2:301-10.[CrossRef][Medline]
[Order article via Infotrieve]
- Chien Y., Frohlich ED, MacPhee AA et al. Quinaprilat increases total body vascular compliance in rats with myocardial infarction. J Cardiovasc Pharmacol 1992;19:430-4.[Web of Science][Medline]
[Order article via Infotrieve]
- Spat A., Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004;84:489-539.[Abstract/Free Full Text]
- Anderson TJ, Elstein E., Haber H. et al. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000;35:60-6.[Abstract/Free Full Text]
- Lyons D., Webster J., Benjamin N. Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol 1997;51:373-8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Jorde UP, Ennezat PV, Lisker J. et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844-6.[Abstract/Free Full Text]
- Jorde UP, Vittorio T., Katz SD et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002;106:1055-7.[Abstract/Free Full Text]
- Struthers AD The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004;6:539-45.[Abstract/Free Full Text]
- van de Wal RM, Plokker HW, Lok DJ et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006;106:367-72.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Watanabe K., Ma M., Wen J. et al. Comparative effects of quinapril with enalapril in rats with heart failure. Pharmacology 2004;71:157-61.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 8, No. 4,
200-204 (2007)
DOI: 10.3317/jraas.2007.025
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
